The recently heightened awareness of racial discrimination coupled with COVID-19’s disproportionate toll on disadvantaged communities has spurred the need for change. Yet the lack of equity and representation of minority groups in clinical research has been an open concern for decades.

Attendees will learn how to optimize patient diversity and inclusivity of clinical trials, and build an understanding of the following:

  • Obstacles that restrict patient diversity in clinical trials
  • How to harness societal awareness to overcome historically entrenched healthcare injustice
  • How clinical researchers can strike the correct balance of scientific and ethical imperatives to ensure equitable access and outcomes in clinical research
  • Examples of how sponsors, patients and investigators have overcome historical biases in clinical trials
  • If and how innovative policy mandates and reforms can contribute to achieving equitable access and participation in clinical research

Featured Speakers

Worta McCaskill-Stevens, MD, MS

Medical Oncologist, Chief
Community Oncology and Prevention Trials Research Group
National Cancer Institute

Dr. Worta McCaskill-Stevens is a Medical Oncologist and Chief of the Community Oncology and Prevention Trials Research Group, which houses the NCI Community Oncology Research Program (NCORP), a community-based clinical trials network. She is a member of the Early Breast Cancer Clinical Trialist Group (Oxford, UK); and is a member of NCI’s Breast Cancer Steering Committee.

Tuya Pal, MD

Associate Director
Cancer Health Disparities
Vanderbilt-Ingram Cancer Center

Tuya Pal is Associate Director for Cancer Health Disparities, Ingram Professor of Cancer Research, and Professor of Medicine at Vanderbilt-Ingram Cancer Center. Her research is focused on identification of basic and clinical research: genetic risk factors that place individuals at a higher risk for cancer, as well as strategies to reduce this risk. Tuya is the incoming Editor-in-Chief of the National Cancer Institute’s Physician Daily Query (PDQ) Cancer Genetics Editorial Board.

Tuya is also Vice Chair of the National Comprehensive Cancer Network® (NCCN) Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Panel.

Jeff Elton, PhD

Chief Executive Officer
ConcertAI

Jeff Elton is CEO of ConcertAI, a precision oncology company working with the American Society of Clinical Oncology’s CancerLinQ and U.S. FDA to advance the use of RWD for pre- and post-approval regulatory submissions, outcomes studies, and value-based care. 

He has over 25 years of experience as a global executive and consultant in the healthcare and life sciences industry. He was previously Managing Director, Accenture Strategy/Patient Health and SVP of Strategy and Global Chief Operating Officer at Novartis Institute of Biomedical Research. He is the co-author of the widely-cited book, Healthcare Disrupted. Jeff is currently a board member of the Massachusetts Biotechnology Council.

Rachele Berria, MD, PhD

Vice President and Medical Head
US BioPharmaceuticals
AstraZeneca

Rachele Berria is the Vice President and Medical Head for US biopharmaceuticals at AstraZeneca, where she is a key player in overseeing the development of 10+ novel MoA-based therapies in both Academia and Industry settings. She is a pioneer of the use of technology to uncover treatment responders, and advocates for randomized pragmatic trials to mirror real world, clinical decision-making, draw cost-effectiveness measures and greater collaboration among payers and providers across the healthcare ecosystem.

Warren Whyte, PhD - Moderator

Vice President Scientific Partnerships and Customer Success
ConcertAI

Warren currently serves as Vice President of Scientific Partnerships at ConcertAI, where he led the launch of ERACE, or Engaging Research to Achieve Cancer Care Equity. The over-arching theme of his work is putting a spotlight on health disparities to promote health equity. The initiatives and partnerships formed under ERACE reaffirm Warren's commitment to moving beyond descriptions of differences in cancer outcomes toward achievement of more equitable outcomes and making a meaningful difference in the lives of all cancer patients.

Prior to ConcertAI, Warren worked at Accenture, where he led the strategic delivery of RWE offerings for leading drug and medical device companies. Dr. Whyte has published in several peer-reviewed scientific journals. He has a BS in molecular and cell biology from Cornell University and a PhD in genomics from MIT.

NOW AVAILABLE ON DEMAND